Acorda Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
December 02 2014 - 6:00AM
Business Wire
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that
Michael Rogers, Chief Financial Officer, and Andrew Blight, Chief
Scientific Officer, will present at the 26th Annual Piper Jaffray
Healthcare Conference in New York on Tuesday, December 2 at
11:00am.
A live audio webcast of the presentation can be accessed under
“Investor Events” in the Investor section of the Acorda website at
www.acorda.com, or you may use the link:
http://www.media-server.com/m/p/e2k2247a
Please log in approximately 5 minutes before the scheduled time
of the presentations to ensure a timely connection. An archived
version of this webcast will be available until January 2, 2015 on
the Investors section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company
focused on developing therapies that improve the lives of people
with neurological disorders.
Acorda markets three FDA-approved therapies including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to
improve walking in patients with multiple sclerosis (MS), as
demonstrated by an increase in walking speed.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy. This
pipeline addresses a range of disorders including post-stroke
deficits, Parkinson’s disease, epilepsy, stroke, peripheral nerve
damage, spinal cord injury, neuropathic pain, and heart
failure.
For more information, please visit the Company’s website at:
www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements, other than statements of historical facts,
regarding management's expectations, beliefs, goals, plans or
prospects should be considered forward-looking. These statements
are subject to risks and uncertainties that could cause actual
results to differ materially, including the ability to realize the
benefits anticipated from the Civitas transaction and to
successfully integrate Civitas' operations into our operations; our
ability to successfully market and sell Ampyra in the U.S.; third
party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or
at all and may impose restrictive prior authorization requirements
that limit or block prescriptions; the risk of unfavorable results
from future studies of Ampyra or from our other research and
development programs, including CVT-301, Plumiaz, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully
market CVT-301, Plumiaz, or any other products under development;
we may need to raise additional funds to finance our expanded
operations and may not be able to do so on acceptable terms; the
occurrence of adverse safety events with our products; delays in
obtaining or failure to obtain regulatory approval of or to
successfully market Fampyra outside of the U.S. and our dependence
on our collaboration partner Biogen Idec in connection therewith;
competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; and, failure to comply with
regulatory requirements could result in adverse action by
regulatory agencies.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this release are made only as of the date hereof, and Acorda
disclaims any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this release.
Acorda TherapeuticsFelicia Vonella,
914-326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024